<p>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 被 16 位分析师给予&#34;中等买入&#34;的平均评级，MarketBeat Ratings 报告称。四位研究分析师给予该股票持有评级，十一位给予买入评级，一位给予强烈买入评级。过去一年更新股票覆盖的经纪人中，平均 1 年价格目标为 75.56 美元。</p>
<ul>
<li>Beam Therapeutics 因基因疗法许可支付而大幅上涨</li>
</ul>
<p>近期有多位股票分析师对该股发表意见。瑞银集团将 Apellis Pharmaceuticals 的目标股价从 89.00 美元下调至 85.00 美元，并在 5 月 8 日星期三的研究报告中为该公司设定了&#34;买入&#34;评级。摩根大通将 Apellis Pharmaceuticals 的股价目标从 78.00 美元上调至 79.00 美元，并在 3 月 6 日星期三的研究报告中为该股设定了&#34;超重&#34;评级。Piper Sandler 在 5 月 31 日星期五对 Apellis Pharmaceuticals 的股票进行了覆盖。他们给出了&#34;中性&#34;评级，并为该公司设定了 46.00 美元的目标股价。富国银行在 5 月 23 日星期四的报告中将 Apellis Pharmaceuticals 的目标股价从 57.00 美元下调至 48.00 美元，并为该公司设定了&#34;等权重&#34;评级。最后，花旗集团在 5 月 8 日星期三的报告中将 Apellis Pharmaceuticals 的股价目标从 67.00 美元下调至 60.00 美元，并为该公司设定了&#34;买入&#34;评级。</p>
<p><strong>查看我们对 APLS 的最新分析</strong></p>
<h2>Apellis Pharmaceuticals 股价下跌 7.6%</h2>
<ul>
<li>小市值股是市场下跌的前兆吗？</li>
</ul>
<p>APLS 股票周五开盘价为 38.36 美元。该公司的市值为 46.6 亿美元，市盈率为-11.09，贝塔系数为 0.95。Apellis Pharmaceuticals 的一年最低价为 19.83 美元，最高价为 92.22 美元。该公司的 50 日移动平均股价为 42.60 美元，200 日移动平均股价为 54.82 美元。公司的资产负债比为 0.35，流动比率为 3.77，速动比率为 3.02。</p>
<p>Apellis Pharmaceuticals (NASDAQ: APLS) 在 5 月 7 日星期二公布了其财报。该公司本季度每股亏损为 0.54 美元，符合市场预期。本季度公司营收为 1.7233 亿美元，超过分析师预期的 1.6337 亿美元。Apellis Pharmaceuticals 的净利润率为-79.67%，净资产回报率为-160.77%。Apellis Pharmaceuticals 的季度营收同比增长 284.3%。去年同期，该公司每股亏损为 1.56 美元。卖方分析师预计，Apellis Pharmaceuticals 本财年的每股收益将为-1.1 美元。</p>
<h2>内部交易活动</h2>
<p>在其他 Apellis Pharmaceuticals 的消息中，首席财务官 Timothy Eugene Sullivan 于 4 月 1 日星期一出售了该公司股票的 4,000 股。股票均价为 58.66 美元，总交易额为 234,640.00 美元。此次交易后，首席财务官现持有公司股票 93,338 股，价值约 5,475,207.08 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过 SEC 网站查阅。此外，内部人员 Pascal Deschatelets 于 4 月 8 日星期一以 54.17 美元的均价出售了公司的 69,107 股股票。交易总额为 3,743,526.19 美元。该内部人员现直接持有公司 1,115,983 股股票，价值 60,452,799.11 美元。此次交易的披露信息可在此处找到。上一季度，内部人员共出售了价值 8,771,758 美元的公司股票 189,014 股。目前公司股份的 6.80% 由公司内部人员持有。</p>
<h2>Apellis Pharmaceuticals 的机构交易</h2>
<p>近期，一些大型投资者对该公司的持股进行了调整。先锋集团在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 0.9%。先锋集团现在拥有该公司的 9,555,678 股股票，价值 572,003,000 美元，在此期间增持了 85,701 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 38.0%。Price T Rowe Associates Inc. MD 现在拥有该公司的 2,460,339 股股票，价值 147,277,000 美元，在此期间增持了 677,098 股。Assenagon Asset Management S.A.在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 109.6%。Assenagon Asset Management S.A.现在拥有该公司的 2,145,004 股股票，价值 128,400,000 美元，在此期间增持了 1,121,497 股。Polar Capital Holdings Plc 在第三季度将其在 Apellis Pharmaceuticals 的持股比例提高了 126.6%。Polar Capital Holdings Plc 现在拥有该公司的 1,053,875 股股票，价值 40,089,000 美元，在此期间增持了 588,875 股。最后，挪威国家银行在第四季度新建了一个 Apellis Pharmaceuticals 的持仓，价值 56,640,000 美元。96.29% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>Apellis Pharmaceuticals 公司简介（获取免费报告）</h2>
<p>Apellis Pharmaceuticals, Inc.是一家处于商业阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗化合物，用于治疗自身免疫性和炎症性疾病。该公司提供 EMPAVELI 用于治疗周期性夜间血红蛋白尿、C3 肾小球病和免疫复合物膜增生性肾小球肾炎，以及造血干细胞移植相关的血栓性微血管病; 以及 SYFOVRE 用于治疗与年龄相关性黄斑变性和地理性萎缩症（GA）相关的地理性萎缩症。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们比 Apellis Pharmaceuticals 更喜欢的股票</li>
<li>如何投资保险公司：指南</li>
<li>高通股票：尽管波动性，AI 驱动增长</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Salesforce 股票：会议总结，AI 聚焦和预测</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>CAVA 是否过度扩张？仔细研究这只高飞股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ Operation Replace Biden is a Go（来自 Freeport Society）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5"/></p>
<h2>现在是否值得投资$1,000 在 Apellis Pharmaceuticals？</h2>
<p>在考虑投资 Apellis Pharmaceuticals 之前，您需要听到这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票清单... Apellis Pharmaceuticals 不在其中。</p>
<p>虽然 Apellis Pharmaceuticals 目前在分析师中具有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

APLS

<p>Apellis Pharmaceuticals, Inc.收到了分析师的 “中等买入” 评级。该股票被十一位分析师评为买入，四位分析师评为持有。该股票的平均目标价格为 75.56 美元。公司上个季度的财务结果显示每股亏损 0.54 美元，符合预期。内部人士已经大量出售公司股票</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been given an average rating of &#34;Moderate Buy&#34; by the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $75.56.</p>
<ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 被 16 位分析师给予&#34;中等买入&#34;的平均评级，MarketBeat Ratings 报告称。四位研究分析师给予该股票持有评级，十一位给予买入评级，一位给予强烈买入评级。过去一年更新股票覆盖的经纪人中，平均 1 年价格目标为 75.56 美元。</p>
<ul>
<li>Beam Therapeutics 因基因疗法许可支付而大幅上涨</li>
</ul>
</div><p>Several equities analysts recently weighed in on the stock. UBS Group cut their target price on shares of Apellis Pharmaceuticals from $89.00 to $85.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, May 8th. JPMorgan Chase &amp; Co. lifted their price objective on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, March 6th. Piper Sandler began coverage on shares of Apellis Pharmaceuticals in a report on Friday, May 31st. They issued a &#34;neutral&#34; rating and a $46.00 target price for the company. Wells Fargo &amp; Company lowered their target price on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, May 23rd. Finally, Citigroup decreased their price objective on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 8th.</p>
<div class="lb-trans"><p>近期有多位股票分析师对该股发表意见。瑞银集团将 Apellis Pharmaceuticals 的目标股价从 89.00 美元下调至 85.00 美元，并在 5 月 8 日星期三的研究报告中为该公司设定了&#34;买入&#34;评级。摩根大通将 Apellis Pharmaceuticals 的股价目标从 78.00 美元上调至 79.00 美元，并在 3 月 6 日星期三的研究报告中为该股设定了&#34;超重&#34;评级。Piper Sandler 在 5 月 31 日星期五对 Apellis Pharmaceuticals 的股票进行了覆盖。他们给出了&#34;中性&#34;评级，并为该公司设定了 46.00 美元的目标股价。富国银行在 5 月 23 日星期四的报告中将 Apellis Pharmaceuticals 的目标股价从 57.00 美元下调至 48.00 美元，并为该公司设定了&#34;等权重&#34;评级。最后，花旗集团在 5 月 8 日星期三的报告中将 Apellis Pharmaceuticals 的股价目标从 67.00 美元下调至 60.00 美元，并为该公司设定了&#34;买入&#34;评级。</p>
</div><p><strong>View Our Latest Analysis on APLS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 APLS 的最新分析</strong></p>
</div><h2>Apellis Pharmaceuticals Stock Down 7.6 %</h2>
<ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股价下跌 7.6%</h2>
<ul>
<li>小市值股是市场下跌的前兆吗？</li>
</ul>
</div><p>Shares of APLS stock opened at $38.36 on Friday. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -11.09 and a beta of 0.95. Apellis Pharmaceuticals has a one year low of $19.83 and a one year high of $92.22. The company's fifty day moving average price is $42.60 and its 200-day moving average price is $54.82. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.77 and a quick ratio of 3.02.</p>
<div class="lb-trans"><p>APLS 股票周五开盘价为 38.36 美元。该公司的市值为 46.6 亿美元，市盈率为-11.09，贝塔系数为 0.95。Apellis Pharmaceuticals 的一年最低价为 19.83 美元，最高价为 92.22 美元。该公司的 50 日移动平均股价为 42.60 美元，200 日移动平均股价为 54.82 美元。公司的资产负债比为 0.35，流动比率为 3.77，速动比率为 3.02。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). The company had revenue of $172.33 million during the quarter, compared to analysts' expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. Apellis Pharmaceuticals's quarterly revenue was up 284.3% on a year-over-year basis. During the same period last year, the company posted ($1.56) earnings per share. Sell-side analysts expect that Apellis Pharmaceuticals will post -1.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals (NASDAQ: APLS) 在 5 月 7 日星期二公布了其财报。该公司本季度每股亏损为 0.54 美元，符合市场预期。本季度公司营收为 1.7233 亿美元，超过分析师预期的 1.6337 亿美元。Apellis Pharmaceuticals 的净利润率为-79.67%，净资产回报率为-160.77%。Apellis Pharmaceuticals 的季度营收同比增长 284.3%。去年同期，该公司每股亏损为 1.56 美元。卖方分析师预计，Apellis Pharmaceuticals 本财年的每股收益将为-1.1 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $58.66, for a total transaction of $234,640.00. Following the sale, the chief financial officer now owns 93,338 shares of the company's stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of the business's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $58.66, for a total transaction of $234,640.00. Following the sale, the chief financial officer now owns 93,338 shares of the company's stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the company's stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares in the company, valued at $60,452,799.11. The disclosure for this sale can be found here. In the last quarter, insiders sold 189,014 shares of company stock worth $8,771,758. 6.80% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Apellis Pharmaceuticals 的消息中，首席财务官 Timothy Eugene Sullivan 于 4 月 1 日星期一出售了该公司股票的 4,000 股。股票均价为 58.66 美元，总交易额为 234,640.00 美元。此次交易后，首席财务官现持有公司股票 93,338 股，价值约 5,475,207.08 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过 SEC 网站查阅。此外，内部人员 Pascal Deschatelets 于 4 月 8 日星期一以 54.17 美元的均价出售了公司的 69,107 股股票。交易总额为 3,743,526.19 美元。该内部人员现直接持有公司 1,115,983 股股票，价值 60,452,799.11 美元。此次交易的披露信息可在此处找到。上一季度，内部人员共出售了价值 8,771,758 美元的公司股票 189,014 股。目前公司股份的 6.80% 由公司内部人员持有。</p>
</div><h2>Institutional Trading of Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 的机构交易</h2>
</div><p>Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Apellis Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company's stock valued at $572,003,000 after purchasing an additional 85,701 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company's stock valued at $147,277,000 after purchasing an additional 677,098 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company's stock valued at $128,400,000 after purchasing an additional 1,121,497 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company's stock valued at $40,089,000 after purchasing an additional 588,875 shares during the period. Finally, Norges Bank acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth $56,640,000. 96.29% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>近期，一些大型投资者对该公司的持股进行了调整。先锋集团在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 0.9%。先锋集团现在拥有该公司的 9,555,678 股股票，价值 572,003,000 美元，在此期间增持了 85,701 股。Price T Rowe Associates Inc. MD 在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 38.0%。Price T Rowe Associates Inc. MD 现在拥有该公司的 2,460,339 股股票，价值 147,277,000 美元，在此期间增持了 677,098 股。Assenagon Asset Management S.A.在第四季度将其在 Apellis Pharmaceuticals 的持股比例提高了 109.6%。Assenagon Asset Management S.A.现在拥有该公司的 2,145,004 股股票，价值 128,400,000 美元，在此期间增持了 1,121,497 股。Polar Capital Holdings Plc 在第三季度将其在 Apellis Pharmaceuticals 的持股比例提高了 126.6%。Polar Capital Holdings Plc 现在拥有该公司的 1,053,875 股股票，价值 40,089,000 美元，在此期间增持了 588,875 股。最后，挪威国家银行在第四季度新建了一个 Apellis Pharmaceuticals 的持仓，价值 56,640,000 美元。96.29% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Apellis Pharmaceuticals Company Profile (Get Free Report</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司简介（获取免费报告）</h2>
</div><p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.是一家处于商业阶段的生物制药公司，专注于通过抑制补体系统来发现、开发和商业化治疗化合物，用于治疗自身免疫性和炎症性疾病。该公司提供 EMPAVELI 用于治疗周期性夜间血红蛋白尿、C3 肾小球病和免疫复合物膜增生性肾小球肾炎，以及造血干细胞移植相关的血栓性微血管病; 以及 SYFOVRE 用于治疗与年龄相关性黄斑变性和地理性萎缩症（GA）相关的地理性萎缩症。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>Qualcomm Stock: AI-Powered Growth Despite Volatility</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Salesforce Stock: Meeting Recap, AI Focus, and Forecast</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Is CAVA Overextended? A Closer Look at This High-Flying Stock</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>五只我们比 Apellis Pharmaceuticals 更喜欢的股票</li>
<li>如何投资保险公司：指南</li>
<li>高通股票：尽管波动性，AI 驱动增长</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Salesforce 股票：会议总结，AI 聚焦和预测</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>CAVA 是否过度扩张？仔细研究这只高飞股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=APLS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Operation Replace Biden is a Go (From The Freeport Society)(Ad)</p>
<div class="lb-trans"><p>→ Operation Replace Biden is a Go（来自 Freeport Society）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8589&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Apellis Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Apellis Pharmaceuticals？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Apellis Pharmaceuticals 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票清单... Apellis Pharmaceuticals 不在其中。</p>
</div><p>While Apellis Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apellis Pharmaceuticals 目前在分析师中具有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) 获得分析师一致推荐为 “适度买入”